What type of treatment is reasonable for older patients with NSTE-ACS?
Bivalirudin, rather than a GP IIb/IIIa inhibitor plus UFH, is reasonable in older patients with NSTE- ACS, both initially and at PCI, given similar efficacy but less bleeding risk. It is also reasonable to choose CABG over PCI in older patients with NSTE-ACS who are appropriate can- didates, particularly those with diabetes mellitus or complex 3-vessel CAD (eg, SYNTAX score >22), with or without involvement of the proximal LAD artery, to reduce cardiovascular disease events and readmission and to improve survival.